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Abstract
Background: The promyelocytic leukemia (PML) protein participates in a number of cellular processes, including
transcription regulation, apoptosis, differentiation, virus defense and genome maintenance. This protein is
structurally organized into a tripartite motif (TRIM) at its N-terminus, a nuclear localization signal (NLS) at its central
region and a C-terminus that varies between alternatively spliced isoforms. Most PML splice variants target the
nucleus where they define sub-nuclear compartments termed PML nuclear bodies (PML NBs). However, PML
variants that lack the NLS are also expressed, suggesting the existence of PML isoforms with cytoplasmic functions.
In the present study we expressed PML isoforms with a mutated NLS in U2OS cells to identify potential
cytoplasmic compartments targeted by this protein.
Results: Expression of NLS mutated PML isoforms in U2OS cells revealed that PML I targets early endosomes, PML
II targets the inner nuclear membrane (partially due to an extra NLS at its C-terminus), and PML III, IV and V target
late endosomes/lysosomes. Clustering of PML at all of these subcellular locations depended on a functional TRIM
domain.
Conclusions: This study demonstrates the capacity of PML to form macromolecular protein assemblies at several
different subcellular sites. Further, it emphasizes a role of the variable C-terminus in subcellular target selection and
a general role of the N-terminal TRIM domain in promoting protein clustering.
Background
The PML protein participates in several different cellu-
lar functions, including transcription regulation, differ-
entiation, virus defence and tumour suppression [1-4].
In addition, this protein represents one of the two
fusion partners in the PML/retinoic acid receptor alpha
(RARA) fusion oncoprotein, which supports tumorigen-
esis in patients with acute promyelocytic leukemia [5,6].
PML belongs to a group of more than 70 different
human proteins commonly referred to as the TRIM
family of proteins. These proteins are characterized by
the presence of a tripartite motif (TRIM) at their N-
terminus, which generally comprises three different struc-
tural elements, including a RING domain, one or two
B-boxes and a coiled coil. The C-terminal region of these
proteins typically contains different types of functional
domains and may vary between protein isoforms due to
alternative pre-mRNA splicing [7,8]. Some common func-
tions of TRIM family members have been identified. For
example, a number of members appear to function in the
innate immune defence against viruses and several have
been shown to possess ubiquitin ligase activity [7,9,10]. In
addition, TRIM family proteins appear to have a general
propensity to form macromolecular protein assemblies at
various subcellular compartments [8,11,12]. It is not clear,
however, how the conserved structural organization of
TRIM family members contributes to these functions at
the molecular level.
A unique feature of the PML protein is its ability to
support the structural integrity of nuclear compartments
called PML nuclear bodies (PML NBs). These structures
can readily be detected by immunofluorescence micro-
scopy as numerous foci within the nucleus, and they
recruit a multitude of different proteins with diverse
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formation of these structures is facilitated by the TRIM
domain, SUMO conjugated residues and a SUMO inter-
acting motif [13-15].
The PML protein is expressed as several alternatively
spliced isoforms, and a selected group of these have
been designated PML I through PML VII [16,17]. The
PML splice variants identified to date contain identical
N-termini, including the TRIM domain, whereas the
C-termini vary considerably among different isoforms. It
is therefore likely that the N-terminus performs a func-
tion that is shared by the different isoforms and that the
C -terminal variable domain contributes to isoform-
specific functions. In agreement with this, some iso-
form-specific functions of PML have been identified
[18-21]. The variability of the PML C-termini probably
contributes significantly to the ability of PML to partici-
pate in a large variety of different cellular processes.
Although most PML isoforms target PML NBs, splice
variants lacking the central nuclear localization signal
(herein referred to as NLS6 because it originates from
exon 6 of the PML pre-mRNA) have also been identified
[22] and may therefore have cytoplasmic functions
[16,23,24]. In addition, the PML I isoform is known
to contain a nuclear export domain at its variable C-
terminus, suggesting that it may shuttle between the
nucleus and the cytoplasm [25]. To identify potential
cytoplasmic PML targets, we have analysed the subcellu-
lar distribution of different PML isoforms containing a
mutated NLS6 in the osteosarcoma cell line U2OS. Our
analyses show that PML has the potential to target dif-
ferent subcellular compartments beside PML NBs,
including early endosomes, late endosomes/lysosomes
and the inner nuclear membrane. Subcellular targeting
by PML is determined by the isoform specific C-
terminal sequence as well as by the presence or absence
of a functional NLS6. In addition, the PML TRIM
domain is found to have a general role in protein clus-
tering at each of the different target compartments.
Results
Differential compartment targeting of import-defective
PML isoforms
Previous studies have identified NLS6 as the primary
NLS of the PML protein and PML isoforms encoded by
mRNAs lacking exon 6 are generally thought to have
lost their nuclear import capacity [16,22]. To generate
PML isoforms that are prohibited from entering the
nucleus, we mutated two lysines at position 486 and 487
within NLS6 to alanines in five different PML isoforms
(PML I through PML V; Figure 1A). Transient expres-
sion of His-tagged versions of these mutated proteins,
which we designated PML Inls through PML Vnls, in
U2OS cells revealed variations in subcellular distribution
between different PML isoforms (Figure 1B). PML Inls
was mainly detected as an amorphous staining pattern
at the peri-centriolar region of the cytoplasm, a region
of the cell that contains different types of organelles,
including the trans-golgi apparatus, the endoplasmatic
reticulum, the microtubules organising centre and mito-
chondria (Figure 1B). PML IInls, on the other hand, was
primarily detected at the nuclear periphery. In fact, the
localization of PML IInls appeared to be identical to
that of the wild type PML II protein, indicating that this
PML splice variant is unaffected by mutations that dis-
rupt NLS6 (Figure 1B). Finally, PML IIInls, PML IVnls
and PML Vnls were all found to target circular struc-
tures in the cytoplasm suggestive of large membrane
embedded vesicles. Interestingly, these cytoplasmic com-
partments were reminiscent of those targeted by overex-
pressed PML VII, which represents a naturally occurring
cytoplasmic isoform lacking NLS6 (Figure 1B). By over-
lying the fluorescence images of these circular structures
with phase contrast images, we confirmed that the cyto-
plasmic compartments targeted by PML VII and
import-defective PML III, IV and V represented mem-
brane embedded cytoplasmic vesicles (Figure 1C). Ana-
lysis of endogenous PML in U2OS cells revealed
distribution of this protein mainly to PML NBs. Partial
localization of PML to the nuclear periphery could be
seen in approximately 3% of cells, whereas the presence
of PML at sites of early or late endosomes was generally
undetectable (Figure 1D).
Targeting of early endosomes and late endosomes/
lysosomes by cytoplasmic PML
The experiment described above identified two distinct
cytoplasmic staining patterns for PML lacking a
functional NLS6: an amorphous staining pattern at peri-
centriolar region defined by PML Inls and cytoplasmic
vesicles targeted by PML IIInls, PML IVnls, PML Vnls
and PML VII (Figure 1B and 1C). To identify these
compartments, we performed double immunofluores-
cence labelling of His-PML Inls or His-PML VII and
markers of different cytoplasmic organelles, including
the endoplasmatic reticulum (labelled by anti-PDI), golgi
(labelled by golgin 97), early endosomes (labelled by
anti-EEA1) and late endosomes/lysosomes (labelled by
anti-Lamp1). We did not detect significant co-localiza-
tion between any of the PML isoforms and markers of
Golgi or endoplasmatic reticulum (Figure 2A-C). His-
PML Inls was, however, consistently found to overlap
with or localize to the immediate vicinity of EEA1-
containing early endosomes (Figure 2E). Conversely, the
enlarged cytoplasmic vesicles targeted by His-PML VII
did not associate significantly with early endosomes
(Figure 2F), but were instead found to co-localize with
Lamp1-positive late endosomes/lysosomes (Figure 2H).
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Page 2 of 12Figure 1 Subcellular localization of NLS6-defective PML isoforms. A) Schematic of PML isoforms analyzed in the present study. Regions
containing the RING domain (RING), B-boxes (B), Coiled-coil (CC), the nuclear localization signal encoded by exon 6 (NLS6), the SUMO interaction
motif (SIM) and the PML I-specific nuclear export signal (NES) are shown. B) Representative images showing subcellular localization of His-tagged
PML isoforms with or without a functional NLS6. His-tagged PML was visualized using anti-His antibodies. C) Overlay images showing
fluorescently labelled His-tagged isoform (red) and phase contrast images (green). Magnifications show co-localization of PML and membrane
enclosed vesicles. D) Endogenous PML in U2OS cells. Arrow points to PML at the nuclear periphery.
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Page 3 of 12The cytoplasmic PML Inls was, however, not found to
co-localize significantly with Lamp1 (Figure 2G). To con-
firm that the compartments targeted by His-PML VII
were the same as those accumulating transiently
expressed PML IIInls, PML IVnls and PML Vnls, we per-
formed dual immunofluoresence labelling of Lamp1 and
His-tagged PML proteins in U2OS cells transiently
expressing these NLS6-defective proteins. In addition, we
also performed co-transfection of these PML-expressing
plasmids with a plasmid expressing GFP-Rab7, another
marker of late endosomes/lysosomes. We found that
PML IIInls, PML IVnls, PML Vnls and PML VII all
co-localized with cytoplasmic structures containing
endogenous Lamp1 and transiently expressed GFP-Rab7
(Additional file 1A). Interestingly, we noted that the
Lamp1-positive endosomes, which contained PML VII or
import defective PML isoforms, were enlarged compared
to endosomes detected in non-transfected cells. This
Figure 2 Localization of PML to early endosomes and late endosomes/lysosomes. U2OS cells transiently transfected with plasmids
expressing His-PML Inls or His-PML VII. Cells were labelled using antibodies against His in combination with antibodies against PDI
(endoplasmatic reticulum), Golgin 97 (trans-golgi network), EEA1 (early endosomes) or Lamp1 (late endosomes/lysosomes).
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late endosomes/lysosomes was stimulated by PML
overexpression.
Targeting of the nuclear periphery by PML II
Since ectopically expressed PML II and PML IInls were
found to preferentially localise to the nuclear periphery
upon overexpression in U2OS cells, we wanted to deter-
mine if this PML splice variant associated with the
nuclear lamina, the protein meshwork that lines the
inner nuclear membrane. For these experiments we
used U2OS cells that were stably transduced with a len-
tivirus expressing FLAG-tagged PML II. The stably
transduced FLAG-PML II-expressing cells appeared to
be growing normally compared to untransduced cells
despite the presence of high concentrations of FLAG-
PML II at the nuclear periphery. By performing immu-
nofluorescence labelling of these cells using antibodies
against the FLAG epitope in combination with anti-
lamin A/C or anti lamin B, we found that PML II pre-
ferentially localized to areas of the nuclear periphery
containing weak nuclear lamina staining (Figure 3A).
Further, comparison of cells expressing the PML II iso-
form to cells expressing PML I or PML III from the
same lentivirus vector, revealed that PML II (unlike
PML I or PML III) induced the formation of gaps in the
lamina (Figure 3A). This result suggests that PML II has
the ability to alter nuclear morphology by excluding
lamina from the nuclear membrane. The gaps within
the lamina network formed by PML II were not caused
by caspase-mediated degradation of the nuclear lamina
as treatment with the caspase inhibitor Z-VAD had no
inhibitory effect on their formation (data not shown).
Further, immunoblots of proteins extracted from the
PML II expressing cells did not reveal increased levels
of caspase cleavage products relative to PML I or PML
III-expressing cells (data not shown). Thus, the periph-
eral nuclear accumulation of PML II and concomitant
formation of gaps in nuclear lamina does not appear to
be related to apoptosis-induced lamina degradation. As
expected, exclusion of lamina at the nuclear periphery
was also observed for transiently transfected U2OS cells
expressing His-tagged PML IInls (data not shown), indi-
cating that the ability of PMLII to exclude nuclear
lamina was independent of NLS6.
To determine if targeting of PML II to the nuclear
periphery merely represented a phenomenon caused by
PML II overexpression or if also endogenous PML has
the capacity to target these nuclear structures, we exam-
ined endogenously expressed PML in U2OS cells. By
immunofluorescence analysis of untransfected U2OS
cells using antibodies directed against the constant part
of the PML protein (thereby detecting all isoforms), we
observed a small sub-fraction (between 1.5 and 2.5%) of
an asynchronously growing population of U2OS cells
that contained detectable PML lining the nuclear per-
iphery. Interestingly, the number of cells containing
detectable PML at nuclear membrane proximal sites
increased following incubation of the cells with DRAQ5
or Actinomycin D, two reagents that are known to
induce genotoxic stress (Figure 3B). This effect was,
however, not observed following treatment with other
genotoxic stressors/RNA synthesis inhibitors, including
DRB, a-amanitin or hydroxyurea (data not shown), sug-
gesting that recruitment of PML to the nuclear periph-
ery is not caused by all types of genotoxic drugs or
RNA synthesis inhibitors. Importantly, these results
show that endogenous PML has the capacity to target
the nuclear periphery and that recruitment of PML to
these nuclear sites may be induced by certain types of
genotoxic stress.
We also determined the ability of PML II to target the
nuclear periphery in three other cell lines, including
HeLa, GM847 and HaCaT. Interestingly, HaCaT and
HeLa cells did not support re-localization of PML to the
nuclear periphery upon PML II overexpression. Instead,
these cells showed accumulation of PML II in seemingly
normal PML bodies at nuclear sites distal to the nuclear
periphery (Additional file 2). GM847 cells, on the other
hand showed a peripheral localization of overexpressed
PML II that was similar to that seen in U2OS cells
(Additional file 2). Further, the two drugs DRAQ5 and
Actinomycin D were found to significantly induce re-
localization of PML to nuclear periphery only in U2OS
and GM847 cells (the same cell lines as those support-
ing nuclear periphery targeting of PML II) but not in
HaCaT or HeLa Cells (data not shown). This result
shows that the ability of PML to target nuclear mem-
brane proximal sites is largely cell-type dependent.
PML II contains functional domains at the C-terminus that
facilitate transport across the nuclear membrane and
targeting of the nuclear periphery
Since PML II is capable of both entering the nucleus
independently of NLS6 as well as targeting the nuclear
periphery, we wanted to determine if these two proper-
ties were induced by the same or by distinct functional
domains within the PML II C-terminal variable domain.
To achieve this, we constructed a series of C-terminally
truncated versions of PML II and PML IInls. By transi-
ent expression of these deletion mutants in U2OS cells
we found that a region between aa 653 and 681 is
required for targeting of the protein to the nuclear per-
iphery (Figure 4). Interestingly, this region overlaps the
aa sequence of PML II that previously has been shown
to be targeted by the Adenovirus 5-encoded protein E4
Orf3, a factor that contributes to distortion of PML
NBs during the course of adenovirus infection [26].
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Page 5 of 12Figure 3 Localization of PML II to the nuclear periphery. A) Immunofluorescence showing FLAG-tagged PML I, II and III in lentivirus
transduced U2OS cells. Overexpressed FLAG-PML II localizes to the nuclear periphery and causes exclusion of lamina. B) Relocalization of
endogenous PML to the nuclear periphery in DRAQ5 or Actinomycin D treated cells. Cells were treated with DRAQ5 (2 μM) or Actinomycin D
(5 μg/ml) for 2 and 4 hours respectively before fixation. Quantitation of results was performed by scoring cells with detectable PML at the
nuclear periphery. The data represent the average of two independent experiments ± standard deviation. The number of cells containing
rearranged PML is significantly increased in drug treated versus control treated cells (p < 0.005).
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found to be lost following deletion of aa 717-767 (Figure
4B). This region does not contain an NLS that can be pre-
dicted based on known NLSs. However, the relatively high
frequency of serines and arginines within this region may
suggest that this protein uses a serine-arginine-rich import
signal similar to those used by a family of pre-mRNA
splicing factors called SR- proteins [27-29]. Importantly,
this experiment shows that distinct sequence elements
within the PML II variable C-terminus are responsible for
nuclear import and targeting of this protein to the nuclear
periphery. This suggests the existence of at least two dif-
ferent functional domains that are unique for the PML II
isoform.
Figure 4 Sub cellular distribution of PML II containing C-terminal truncations. A) Nucleotide sequence of PML II-specific C-terminal region.
The regions effecting NLS6 independent nuclear localization and targeting of nuclear periphery are highlighted in red and green, respectively.
B) Subcellular distribution of His-PML II mutants in transiently transfected U2OS cells.
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and the nuclear periphery by PML depends on a
functional TRIM domain
The TRIM domain has previously been shown to be
important for several PML functions. In addition, this
motif has been demonstrated to be important for target-
ing of PML to PML NBs [14]. To determine if the
TRIM domain is required for directing PML to early
endosomes, late endosomes/lysosomes and the nuclear
periphery, we generated a set of mutated plasmid con-
structs expressing proteins with cysteine-to-serine muta-
tions (C57S and C60S) in two conserved cysteines of the
RING motif of PML. These conserved amino acid sub-
stitutions have been used previously to determine RING
domain functions [14,30]. The RING mutation was
inserted into wild type PML I, PML II and PML VII as
well as in PML Inls and PML IInls. Expression of these
mutants in U2OS cells revealed a clear dependence of a
functional RING motif for proper subcellular targeting.
PML VIIring was completely impaired in its ability to
target late endosomes/lysosomes. Instead, this mutant
was found to distribute diffusely throughout the cyto-
plasm of the transfected cell (Figure 5I-J). Similarly,
PML I, which normally localizes to PML NBs, was
found to distribute diffusely within the nucleus in the
absence of a functional RING motif (Figure 5A-B).
Further, the doubly mutated PML Inls/ring, which con-
tains mutationally disrupted NLS6 and RING motifs,
was found to distribute diffusely in the cytoplasm and
was completely impaired in targeting early endosomes
(Figure 5C-D). Finally, we found that PML IIring com-
pletely lost its ability to target the nuclear periphery
upon overexpression in U2OS cells and was, instead,
found to cluster within nuclear aggregates within the
cell nucleus (Figure 5E-F). The doubly mutated PML
IIring/nls protein exhibited a similar subcellular distri-
bution as that seen for PML IIring (Figure 5G-H), con-
firming the ability of the PML II C-terminus to direct
this protein to the nucleus in a NLS6-independent man-
ner. The observation that PML IIring formed nuclear
Figure 5 PML clustering requires a functional TRIM domain. U2OS cells were transfected with plasmids expressing the indicated PML
isoforms and mutants. PML was visualized using an anti His antibody.
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NBs was surprising since previous studies have sug-
gested that the formation of these nuclear structures
depend on a functional RING domain. Interestingly, the
structures formed by the mutated protein also recruited
other PML NB resident proteins including CBP, SUMO
and Daxx (Additional file 3), suggesting that they may
have some features in common with normal PML NBs.
Discussion
The present study identifies early endosomes, late endo-
somes/lysosomes and structures at the inner nuclear
membrane as targets for PML isoforms lacking a func-
tional NLS6 (Table 1). The selection of target organelles
by each of the isoforms appears to be regulated by their
C-terminal variable domain. In addition, the ability of
the various PML isoforms to sequester at their respec-
tive cellular sites is found to be largely dependent on
the presence of a functional TRIM domain. Thus, dis-
tinct functional elements at both the N-terminal as well
as the C-terminal portion of PML may cooperate to
achieve correct subcellular localization of the protein.
Such dual requirement for functions at the N-terminus
and C-terminus for proper protein localization may
represent a general trait of TRIM family proteins. This
is suggested by a general ability of several proteins con-
taining a TRIM domain to cluster at specific cellular
sites and by the conserved organization of this family of
proteins into a constant N-terminal region (containing
the TRIM domain) and a flexible C-terminal tail that
may contain different types of functional domains.
The ability of PML to target early and late endosomes
may reflect a role for PML in endosome trafficking.
A functional association of PML with early endosomes
has previously been reported for a splice variant of PML
that lacks exon 5 and 6 and that contains an N-terminal
configuration similar to that of PML IV. In this case,
cytoplasmic PML was found to function in TGFb-
mediated signaling through interactions with SMAD1,
SMAD2 and SARA at early endosomes [23]. Further,
since several viruses and bacteria are known to exploit
e n d o s o m a lt r a f f i c k i n gr o u t sa sam e a n st oi n v a d et h e i r
host, the ability of PML to target these cytoplasmic
organelles may also reflect a role of this protein in the
cellular defense against pathogens. In agreement with
this, PML represents an interferon responsive gene
(which is characteristic for genes involved in the innate
immune response) and has been shown to restrict repli-
cation of certain viruses [3,31,32]. In a recent study, pro-
duction of splice variants of PML lacking exon 5 and 6
was shown to be increased in interferon treated and
HSV1-infected cells [24]. This finding suggests the exis-
tence of a regulatory mechanism whereby cells respond
to virus infection by altering the splice pattern of PML
to obtain increased expression of cytoplasmic versus
nuclear PML. The present study indicates that PML
proteins produced by mRNA species lacking exon 5 and
6 will be expected to target late endosomes/lysosomes.
Further studies are needed to determine if PML exerts
its antiviral property by interfering with endosomal or
lysosomal functions.
A limitation of the present study is that we were
unsuccessful in detecting endogenous PML within early
or late endosomes by immunofluorescence labeling
using anti-PML antibodies. In fact, PML in most types
of cultured mammalian cells are primarily detected
within PML NBs where it is most highly concentrated.
We cannot fully exclude the possibility that the ectopi-
cally expressed NLS6-defective PML detected in endo-
somes represents protein aggregates that are in the
process of being cleared from the cell by lysosome-
mediated degradation. However, several observations
suggest a functional role of PML at these locations.
First, the observed subcellular distribution of PML to
late endosomes is dependent on a functional RING
motif. This suggests that a functional TRIM is required
for endosome targeting. Second, the cytoplasmic stain-
ing of PMLVII as well as PML IIInls, PML IVnls and
PML Vnls seem to be present mostly at the exterior of
these organelles and not at their interior as would be
expected if PML was engulfed by lysosomes. Third, the
PML isoforms expressed in the cytoplasm enhances the
size of late endosomes/lysosomes, suggesting a stimula-
tory role of cytoplasmic PML on these compartments.
Lastly, overexpressed NLS6-proficient PML proteins can
also be observed to form aggregates in the cytoplasm
that are readily detected by immunofluorescence, but
for these proteins we have never observed co-localiza-
tion with the lysosomal marker proteins Lamp1 or
Rab7. Thus, NLS6 may have a direct role in preventing
PML isoforms that are destined to target the nucleus
from interacting with late endosome/lysosomes. The PML
protein was recently identified in a proteomic screen for
phagosomes resident proteins [33]. Thus, even though
PML generally is undetectable by immunofluorescence in
Table 1 Target compartments of wild-type and nuclear
import-defective PML isoforms in U2OS cells
PML
isoform
Wild type Nuclear import-defective
mutant
PML I PML NBs Early endosomes
PML II Nuclear periphery Nuclear periphery
PML III PML NBs Late endosomes/lysosomes
PML IV PML NBs Late endosomes/lysosomes
PML V PML NBs Late endosomes/lysosomes
PML VII Late endosomes/
lysosomes
Not applicable
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Page 9 of 12most cytoplasmic compartments, this protein may be pre-
sent in organelles such as endosomes and phagosomes at
levels that are undetectable by antibodies that we have
available.
PMLII overexpressed in U2OS cells was found to
primarily target the inner nuclear membrane. Distribu-
tion of PMLII to these nuclear sites was also noted in a
previous study following expression of this isoform in
Chinese hamster ovary cells [34]. This particular distri-
bution of PML appears to be highly cell type specific as
PMLII expressed in HaCaT or HeLa cells exhibited
PML clusters at more central regions of the nucleus
consistent with normal PML NB morphology. Interest-
ingly, both cell lines (U2OS and GM847) that were
found to support targeting of PML to the nuclear per-
iphery are ALT cells, cells that use alternative lengthen-
ing of telomeres (ALT) and not telomerase as their
primary mechanism for telomere elongation [35,36]. It
has previously been shown that ALT cells contain spe-
cial PML NBs termed ALT associated PML bodies
(APBs) that sequester DNA repair proteins and telo-
meric DNA [37]. Thus, the ability to direct PML to the
nuclear periphery may represent an additional pheno-
type that accompanies ALT cells.
So far we have not been able to detect structural com-
ponents of the nuclear periphery that co-localized with
PML at the edge of the nucleus. In fact, both nuclear
lamina as well as nuclear pore complexes (as detected
with the nucleoporin-specific antibody Mab414; data not
shown) were found to be excluded from sites containing
overexpressed PMLII. The association of PML with the
nuclear periphery may reflect a role of this protein in
cellular processes such as transcription regulation, DNA
replication or DNA repair since these cellular processes
are known to be active at nuclear envelope proximal
sites [38-40]. Interestingly, the region of PMLII that we
found to be responsible for inducing nuclear periphery
targeting overlaps the amino acid sequences previously
shown to interact directly with the adenovirus protein
E4 Orf3, which is known to be involved in PML NB dis-
ruption during adenovirus infection [26]. This may indi-
cate that the activity supported by PMLII at the nuclear
periphery represents a barrier that certain viruses need
to overcome in order to achieve successful infection.
The presence of an extra NLS at the C-terminal vari-
able domain of PMLII suggests that some splice variants
of this protein may enter the nucleus even in the
absence of amino acid sequences encoded by exon 6.
Analysis of the C-terminal region of PMLII does not
reveal peptide sequences that match the consensus
sequence of any known NLSs [41]. However, the region
between aa 717 to 767, which in the present study was
shown to be important for import activity, is rich in
arginines and serines. This may suggest the presence of
a serine arginine-rich NLS similar to that used by
SR-proteins, a group of proteins involved in pre-mRNA
splicing [27-29]. The lack of sequence similarity between
NLS6 and the NLS present within PMLII C-terminal
variable region, suggests that PML II uses two distinct
nuclear import routes.
NLS6 seems to represent an unconventional NLS that
may play a central regulatory role in several aspects of
PML trafficking and subcellular localization. Besides
playing an important role in nuclear import, this peptide
sequence has also been shown to be required for target-
ing PML to cytoplasmic PML-containing compartments
referred to as cytoplasmic assemblies of PML and
nucleoporins (CyPNs) [30]. These structures form dur-
ing the mitosis-to-G1 transition of the cell cycle and
seem to be derived directly from post mitotic PML NBs
[30]. NLS6 may also be regulated by SUMOylation since
this peptide sequence is known to contain one of the
three lysine residues that represent SUMO conjugation
sites in PML. However, abrogation of this SUMOylation
site by mutagenesis was found not to affect PML
nuclear import, suggesting a role of this SUMOylation
event that is not directly related to import [22]. Finally,
genome sequencing analysis of patients with an aggres-
sive ATRA-resistant form of APL revealed mutations in
the non-rearranged PML gene that is predicted to cause
premature translation termination of the PML protein
upstream of NLS6 [42]. Based on the data presented in
the present study, such mutants may contribute to
tumorigenesis through interference with late endo-
somes/lysosomes functions.
Conclusions
In this study we have shown that forced expression of
PML in the cytoplasm leads to clustering of this protein
at different types of cellular compartments, including
early endosomes, late endosomes and the inner nuclear
membrane. Since the ability of PML to cluster at each
of these different sites depends on a functional TRIM
domain, our data support the notion that the TRIM
domain plays a general role in protein clustering and
that the alternatively spliced C-terminus of the protein
has a specific role in compartment selection. Further
studies are needed to elucidate potential functions of
PML at early endosomes, late endosomes and the
nuclear periphery.
Methods
Cell-lines and transfection
U2OS cells (human osteosarcoma), GM-847 cells (SV40
transformed human fibroblasts), HaCaT (human kerati-
nocyte) and HeLa (human cervical cancer) were main-
tained in Iscove’s modified Dulbecco’s medium (IMDM;
Bio Whittaker, Belgium) containing 10% foetal calf
Jul-Larsen et al. BMC Molecular Biology 2010, 11:89
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Page 10 of 12serum (PAA, Austria) at 37°C and 5% CO2. Cells were
transfected using the FuGENE6 transfection reagent
(Roche, Switzerland) according to the manufacturer’s
protocol. U2OS cells stably expressing Flag-tagged PML
I, II or III were generated using lentivirus constructs
generously provided by Dr Roger D Everett at MRC vir-
ology unit, Glasgow, UK.
Plasmid constructs
His-tagged PML I through V expressed from a pcDNA3
vector were kindly provided by Dr. K-S Chang at the
University of Texas, Austin, Texas [21]. His-tagged PML
VII and NLS mutants (K486A_K487A) of PML I through
V were described in [30]. The PML II truncation mutants
were made by PCR cloning using the forward primer
(gaagcccagcctatggctgtg) in combination with the reverse
primers (tatgaattcatgcctccccggcgccactggc (1-552), tatgaatt-
caagactggactggcgaggagtg (1-602), tatgaattcagtggacgg-
cagggcgctc (1-652), tatgaattcattgcagctgggcaggatgttc (1-716)
or tatgaattcacaccacggaagacatgtcaag (1-767)). The PCR pro-
duct was then substituted for the PML II specific sequence
of pcDNA3 His-PML II or pcDNA3 His-PML IInls using
the Van91I (Fermentas, Canada) and Eco RI (NEB, MA)
restriction sites. The 1-681 mutant was constructed by
digesting the pcDNA3 His-PML II vector with Apa I
restriction enzyme (Takara, Japan) and re-ligation. This
resulted in the loss of PML II aa 682-829 and formation of
a short, 12 aa, nonspecific tail at the end of the protein.
RING finger mutants of PML I, II and VII were con-
structed by introducing point-mutations (C57S;C60S) to
the respective His-tagged PML isoforms using the Quik-
C h a n g ek i t( S t r a t a g e n e ,C A ) .T h eH i s - P M LI - R Na n d
His-PMLII-RN, RING finger and NLS double mutants,
were constructed by introducing the RING finger and
NLS mutations in two subsequent reactions using the
QuikChange kit. The plasmid expressing GFP-tagged
Rab7 was kindly provided by Dr. Harald Stenmark at
Rikshospitalet, Oslo, Norway.
Immunofluorescence
Cell fixation and immunofluorescence labeling was per-
formed as described previously [43]. Primary antibodies
used were mouse anti-His (HIS-H8), mouse anti-PML
(PG-M3), rabbit anti-PML (H238) mouse anti-Lamp1
(H5G11) and mouse anti-Lamin A/C (636) (all from
Santa Cruz, CA), rabbit anti-Lamin B1 (Abcam, UK)
and mouse anti-Flag (F3165) (Sigma, MO). Secondary
antibodies were FITC or Texas-Red labeled goat antibo-
dies against mouse immunoglobulin subtypes or against
rabbit antisera (Southern Biotech, AL).
Microscopic images were obtained using a Zeiss
LSM510 Meta laser confocal microscope (Zeiss,
Germany) with a 63× oil immersion lens (Zeiss).
Chemicals and treatment
DRAQ5 treatment was performed by adding DRAQ5
(Biostatus, UK) to a final concentration of 2 μM, to the
medium for two hours before fixation. Actinomycin D
treatment was performed by adding Actinomycin D
(Sigma), to a final concentration of 5 μg/ml, for four
hours before fixation. To quantify cells with PML at the
nuclear periphery, cells were counted manually in the
microscope. For each sample, four hundred cells were
counted and scored for the presence of PML staining at
the nuclear periphery. In each case, two independent
parallels were counted.
Additional material
Additional file 1: Co-localization of PML to late endosomes/
lysosomes. A) Immunofluorescence labelling showing co-localization of
His-tagged PML VII with Lamp1 (left panels) or transiently expressed YFP-
Rab7 (right panels). B) Immunofluorescence images showing co-
localization between nuclear import-defective PML isoforms and Lamp1.
Additional file 2: PML II distribution in different cell lines.U 2 O Sa n d
HaCaT cells were stably transduced using a lentivirus expressing FLAG-
tagged PML II. GM847 and HeLa cells were transiently transfected by a
plasmid expressing His-tagged PML II.
Additional file 3: Co-localization of His-PML II, His-PML IIring and
His-PML IInls with PML NB resident proteins. U2OS cells were
transfected with plasmids expressing wt or mutated PML II and
subsequently immunolabeled using an anti His antibody in combination
with antibodies targeting the indicated proteins.
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